The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
<h4>Aim</h4> <p>To characterise the efavirenz steady-state pharmacokinetics in African children using model-based approach, quantifying demographic and genotypic effects on the drug’s disposition, and conduct simulations allowing prediction of optimised doses of efavirenz in this p...
Main Authors: | Bienczak, A, Cook, A, Wiesner, L, Olagunju, A, Mulenga, V, Kityo, C, Kekitiinwa, A, Owen, A, Walker, A, Gibb, D, McIlleron, H, Burger, D, Denti, P |
---|---|
Format: | Journal article |
Published: |
Wiley
2016
|
Similar Items
-
Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
by: Bienczak, A, et al.
Published: (2016) -
The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
by: Bienczak, A, et al.
Published: (2016) -
Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
by: Bienczak, A, et al.
Published: (2017) -
Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial
by: Schomaker, M, et al.
Published: (2024) -
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
by: Oudijk, J, et al.
Published: (2012)